Warning letter
Medlife Pharmacy and Compounding, Inc.: warning letter of Apr 24, 2020
FDA warning letter 607417 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 607417 |
|---|---|
| Company | Medlife Pharmacy and Compounding, Inc. |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Apr 24, 2020 |
| Posted date | May 5, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 201.115, 200.10(b), 211.42(b), 211.67(a), 211.110(a), 211.165(a), 211.166(a), 210.1(b) |
| Inspection city | Irvine |
| Inspection ZIP | 92618-2117 |
| Inspection start date | Apr 9, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: